Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | FPR2 | P25090 | 2/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14499604 | 0.84 | KMT2A (0.60) | KMT2ARAB9ASMN1; SMN2MAPTFPR2 | |
| SCHEMBL11774212 | 0.79 | POLB (0.59) | KMT2ARAB9ASMN1; SMN2MAPTAKR1B1 | |
| SCHEMBL24980367 | 0.76 | AKR1B1 (0.63) | KMT2ASMN1; SMN2MEN1FPR2AKR1B1 | |
| SCHEMBL5622453 | 0.76 | KMT2A (1.00) | KMT2ASMN1; SMN2MEN1FPR2ALDH1A1 | |
| SCHEMBL18356377 | 0.75 | KMT2A (0.76) | KMT2ARAB9ASMN1; SMN2MAPTAKR1B1 | |
| SCHEMBL18355849 | 0.75 | KMT2A (0.76) | KMT2ARAB9ASMN1; SMN2MAPTFPR2 | |
| SCHEMBL10304450 | 0.74 | POLB (0.62) | KMT2ARAB9ASMN1; SMN2MAPTAKR1B1 | |
| SCHEMBL11808078 | 0.74 | KMT2A (0.63) | KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL11638327 | 0.74 | HSD17B10 (0.57) | KMT2ARAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL18356190 | 0.73 | KMT2A (0.79) | KMT2ARAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2530078-A1 | THIAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-1910292-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | KMT2A 1629/4885RAB9A 3025/4885SMN1; SMN2 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.